Pharmaceutical TechnologyOriginal article
Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development
IPO/OfferingoxnimbiPositive
AI Analysis
Summary
Apnimed is conducting a $160 million IPO to fund late-stage development of oxnimbi, a novel oral treatment candidate for obstructive sleep apnoea that could be the first pill approved in this market.
Importance:6/10
Sentiment:
0.60
IPOsleep apnoeaOSAlate-stage developmentfinancing
Related Companies
Read the original article
Published by Pharmaceutical Technology on July 28, 2026 10:26 AM